Danaher acquired Pall Corporation for approximately $13.6B in cash, expanding bioprocess filtration and life sciences tools platform. Pall later combined with Beckman/Leica/SCIEX/Molecular Devices to form Danaher's life sciences segment, which spun off as Veralto/Envista components. Borderline pharma BD — included as platform/diagnostics-level life sciences.